VCYT

VeracyteB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$46.76

-2.2% vs current

Most likely

Base case

60%

Probability

Target price

$39.57

-17.2% vs current

B-

Bear case

20%

Probability

Target price

$28.78

-39.8% vs current

AI sentiment snapshot

Latest data as of 2025-10-29

AI commentary

Market tone around Veracyte is cautiously constructive: recent trade levels sit modestly above the latest official close, indicating some investor support [#PRICE-2025-10-27]. Conversations focus on reimbursement progress and commercial scale; downside concerns center on competition and execution [#SEC][#PR]. Overall narrative is watchful optimism with event-driven volatility likely.

RankAlpha Sentiment AI - 2025-10-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventQuarterly earnings releaseHigh impact

Regular quarterly results can drive short-term share moves via revenue guidance or margin commentary; market historically reacts to volume/coverage updates [#PRICE-2025-10-27].

-eventClinical data or commercial partnership announcementHigh impact

New peer-reviewed clinical results or strategic partnerships could boost adoption and conviction for growth; timing is uncertain [#PR].

-catalystReimbursement / payer coverage expansionHigh impact

Broader reimbursement for key genomic tests (Afirma/Percepta/Envisia) would materially increase addressable market and revenues over multiple quarters [#SEC].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-10-29 • Updated nightlySource: Internal modelMethodology